BTAI BioXcel Therapeutics, Inc.
Healthcare$1.22+7.96%ClosedMarket Cap: $37.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.13
P/S
51.31
EV/EBITDA
-1.98
DCF Value
$-7.83
FCF Yield
-164.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
27.8%
Operating Margin
-7395.0%
Net Margin
-11078.5%
ROE
75.8%
ROA
-221.4%
ROIC
-3439.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $206.0K | -65.5% | $-10.1M | $-12.7M | $— | — |
| Q4 null | $256.0K | 87.5% | $-10.3M | $-12.5M | $— | — |
| FY null | $642.0K | 74.5% | $-50.3M | $-69.9M | $— | — |
| Q3 null | $98.0K | 88.8% | $-14.0M | $-30.9M | $— | — |
| Q2 null | $120.0K | 10.8% | $-15.9M | $-19.2M | $— | — |
| Q1 null | $168.0K | 91.7% | $-10.1M | $-7.3M | $— | — |
| Q4 null | $366.0K | -127.3% | $-10.5M | $-10.9M | $— | — |
| FY null | $2.3M | 5.4% | $-67.2M | $-59.6M | $— | — |
| Q3 null | $214.0K | -446.7% | $-15.3M | $-13.7M | $— | — |
| Q2 null | $1.1M | 94.4% | $-17.3M | $-8.3M | $— | — |
| Q1 null | $582.0K | 72.9% | $-23.9M | $-26.8M | $— | — |
| Q4 2023 | $376.0K | -89.9% | $-19.9M | $-22.3M | $-12.09 | — |